老年人抗胆固醇药物暴露的时间趋势:一项为期25年的基于人口的研究
Amanda Evelo1,2, Silvan Licher3,4, Bruno H Stricker3
1Department of Hospital Pharmacy, Erasmus MC, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.
自1996年以来,老年人的抗胆固醇药物暴露量下降了50%以上. 然而,老年人仍然面临最高的风险,需要在处方方面保持警.
科学领域:
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 抗胆固醇药物暴露与老年人的不良结果有关.
- 建议限制抗胆固醇负担 (ACB),但人口层面的趋势数据很少.
- 这项研究分析了社区居住的老年人中ACB的时间趋势.
研究的目的:
- 估计累计ACB分数为3或以上 (cACB ≥3) 的累计发病率和发病率 (IR).
- 在一个社区居住的老年人群中,在25年内描述cACB≥3的IR变化.
- 为了确定老年人抗胆固醇药物暴露的趋势.
主要方法:
- 使用了基于人口的鹿特丹研究 (1996-2020) 的药房发行记录.
- 使用抗胆固醇认知负担量表和EPHOR专家建议计算cACB分数.
- 确定特定于年龄和性别的IR,并使用5年周期分析时间趋势.
主要成果:
- 从1996年到2020年,cACB≥3的累积发病率为25.3%,为1996年至2020年的25.3%.
- 在1996-2000年至2016-2022年期间,cACB ≥3的发病率下降了54%.
- 86-90岁的个人与66-70岁的人相比,cACB≥3的IR是cACB≥3的1.67倍.
结论:
- 在1996年至2020年期间,社区居住的老年人中,抗胆固醇药物暴露显著减少了50%以上.
- 最年长的个体始终表现出cACB≥3的最高风险.
- 对抗胆固醇药物处方的持续审查至关重要,特别是在脆弱的老年人群中.
更多相关视频
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
06:52Assessment of Dependence in Activities of Daily Living Among Older Patients in an Acute Care Unit
Published on: September 30, 2020
相关概念视频
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Time Course of Drug Effect
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Factors Affecting Drug Response: Overview
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
